Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies

Matthias Meier, Michael Hummel, Matthias Meier, Michael Hummel

Abstract

Type 2 diabetes mellitus (T2DM) is associated with a high risk of complications, essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary and cerebrovascular complications and the target level of glycated hemoglobin (HbA(1c)) in this population remains questionable. We here report the results of 4 recently published randomized controlled trials (ACCORD, ADVANCE, VADT, UKPDS post-trial), which did not demonstrate a significant reduction of cardiovascular events in the intensive group compared to the standard group. On the contrary, in ACCORD, the study with the most ambitious goal (HbA(1c) < 6%), the overall and cardiovascular mortality was greater in the intensive group, although the risk of microangiopathic complications, especially nephropathy, was significantly decreased. VADT suggests that one possibility for the lack of observed effect of intensive therapy could be that the cardiovascular benefit is delayed. This contrasts strongly with the long-term postintervention outcomes of UKPDS, which show a persistent benefit of glycemic control during 10 years of post-trial follow-up ('legacy effect'). Therefore, the best way to protect patients with T2DM against coronary and cerebrovascular disease is to target all cardiovascular risk factors as early as possible by an individualized approach.

Trial registration: ClinicalTrials.gov NCT00000620 NCT00032487 NCT00145925.

Keywords: ACCORD; ADVANCE; UKPDS post-trial; VADT; cardiovascular; glycemic control.

Figures

Figure 1
Figure 1
Evidence-based guideline for antihyperglycemic treatment in patients with T2DM (adopted from the German Diabetes Association [Deutsche Diabetes Gesellschaft/DDG] based on the data from the ACCORD, ADVANCE, VADT and UKPDS post-trial). aReduce HbA1c level to ≤6.5% from ≤7% might be advantageous but only when: – (severe) hypoglycemia is prevented – weight gain does not occur – use of multiple glucose-lowering drugs (>2) or additional insulin therapy can be avoided HbA1c should be measured every 3 months. Therapy should be intensified if/when the target level is missed. In contrast, pharmacological dechallenge and ‘step back’ can be performed if the individual HbA1c remains stable over a longer time.

References

    1. Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med. 2003;348(5):457–459.
    1. Gaede P, Pedersen O. Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes. Ann Med. 2004;36(5):355–366.
    1. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393.
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591.
    1. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192.
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
    1. The Diabetes Control and Complications Trial Research Group The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
    1. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
    1. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
    1. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med. 2008;358(24):2633–2635.
    1. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840.
    1. Karalliedde J, Gnudi L. ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant. 2008;23(6):1796–1798.
    1. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359(15):1618–1620.
    1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6):1011–1053.
    1. Ruilope L. New ADVANCEs in guidelines. J Hypertens Suppl. 2008;26(2):S16–S18.
    1. Mogensen C. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 2003;21(1):S25–S30.
    1. Abuissa H, Jones PG, Marso SP, O’Keefe JH., Jr Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821–826.
    1. The ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
    1. Davis BR, Furberg CD, Wright JT, Jr, Cutler JA, Whelton P, the ALLHAT Collaborative Research Group ALLHAT: Setting the record straight. Ann Intern Med. 2004;141(1):39–46.
    1. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006;17(4 Suppl 2):S25–S29.
    1. D’Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303(6799):385–389.
    1. Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT) – importance then and now. JAMA. 2008;300(11):1343–1345.
    1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
    1. Ruilope L, Hansson L, Zanchetti A. What have we learned from the HOT (hypertension optimal treatment) study? Nephrol Dial Transplant. 1997;12(10):2047–2048.
    1. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576.
    1. American Diabetes Association Standards of medical care in diabetes – 2009. Diabetes Care. 2009;32(Suppl 1):S13–S61.
    1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172.
    1. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H-C, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–399.
    1. Krentz A. Comparative safety of newer oral antidiabetic drugs. Expert Opin Drug Saf. 2006;5(6):827–834.
    1. Krumholz HM, Lee TH. Redefining quality – implications of recent clinical trials. N Engl J Med. 2008;358(24):2537–2539.
    1. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
    1. Milicevic Z, Raz I, Strojek K, Skrha J, Tan M, Wyatt J, et al. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications. 2005;19(2):80–87.
    1. Gerstein H, Yusuf S, Riddle M, Ryden L, Bosch J. Rationale, design, and baseline, Origin Trial Investigators, characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) Am Heart J. 2008;155(1):26–32. 32.e1–e6.
    1. Magee M, Isley W. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97(12A):20G–30G.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe